(Q35192171)

7 August 2017

1 reference

title

Survey of human-use adjuvants (English)

1 reference

7 August 2017

Richard T Kenney

1 reference

7 August 2017

Robert Edelman

series ordinal

1 reference

7 August 2017

publication date

1 April 2003

1 reference

Expert Review of Vaccines

7 August 2017

published in

1 reference

7 August 2017

1 reference

7 August 2017

1 reference

7 August 2017

page(s)

167-188

1 reference

Adjuvants: current status, clinical perspectives and future prospects

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.167

Vaccine technologies: view to the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.167

Adjuvants for human vaccines--current status, problems and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.167

Advances in vaccine adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.167

Overview of vaccine adjuvants: present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.167

The development and use of vaccine adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.167

The immunological synapse: a molecular machine controlling T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.167

Antigen delivery systems and immunostimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.167

The immune system evolved to discriminate infectious nonself from noninfectious self

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.167

Innate immune recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.167

The danger model: a renewed sense of self

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.167

Antigen localisation regulates immune responses in a dose- and time-dependent fashion: a geographical view of immune reactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.167

The instructive role of innate immunity in the acquired immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.167

Antibody and cytokine responses in efferent lymph following vaccination with different adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.167

Mechanisms of stimulation of the immune response by aluminum adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.167

Comparison of adjuvant activities of aluminium phosphate, calcium phosphate and stearyl tyrosine for tetanus toxoid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.167

Vaccines: predicting the risk of allergy and autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.167

Pilot evaluation of influenza virus vaccine (IVV) combined with adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.167

Adverse events and vaccination-the lack of power and predictability of infrequent events in pre-licensure study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.167

Control of Influenza and Poliomyelitis with Killed Virus Vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.167

Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminium hydroxide in muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.167

Response of infants to pertussis vaccine at one week and to poliomyelitis, diphtheria, and tetanus vaccine at six months

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.167

Long-term antibody responses in mice following subcutaneous immunization with ovalbumin entrapped in biodegradable microparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.167

The second international standard for tetanus toxoid (adsorbed).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.167

Development of a guinea pig model to assess immunogenicity of Haemophilus influenzae type b capsular polysaccharide conjugate vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.167

Immunoglobulin E responses to diphtheria and tetanus toxoids after booster with aluminium-adsorbed and fluid DT-vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.167

Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.167

Immunogenicity and adverse effects of inactivated virosome versus alum-adsorbed hepatitis A vaccine: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.167

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.167

Field trial of oral cholera vaccines in Bangladesh

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.167

Adjuvants designed for veterinary and human vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.167

Squalene and squalane emulsions as adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.167

Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.167

Enhancement of antibody responses to influenza B virus haemagglutinin by use of a new adjuvant formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.167

Improvement of hepatitis B vaccine by the use of a new adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.167

Vaccinating guinea pigs with recombinant glycoprotein D of herpes simplex virus in an efficacious adjuvant formulation elicits protection against vaginal infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.167

Validation of a first-generation Epstein-Barr virus vaccine preparation suitable for human use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.167

A formalin-inactivated whole SIV vaccine confers protection in macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.167

Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.167

Bacterial cell wall products as adjuvants: early interferon gamma as a marker for adjuvants that enhance protective immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.167

A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.167

Safety and immunogenicity of a prototype enterotoxigenic Escherichia coli vaccine administered transcutaneously

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.167

Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.167

Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.167

Influenza virus ISCOMs: antibody response in animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.167

The serum antibody response distributed in subclasses and isotypes after intranasal and subcutaneous immunization with influenza virus immunostimulating complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.167

Cellular immune responses in the murine lung to local immunization with influenza A virus glycoproteins in micelles and immunostimulatory complexes (iscoms).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.167

Augmentation of human influenza A virus-specific cytotoxic T lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.167

Genetically-engineered subunit vaccine against feline leukaemia virus: protective immune response in cats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.167

Adjuvant formulation for use in vaccines to elicit both cell-mediated and humoral immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.167

A comparison of commercially available adjuvants for use in research

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.167

Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.167

Recent developments in adjuvants for vaccines against infectious diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.167

Effects of interferons on immune response to a synthetic peptide malaria sporozoite vaccine in non-immune adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.167

Dehydroepiandrosterone (DHEA) treatment reverses the impaired immune response of old mice to influenza vaccination and protects from influenza infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.167

Cytokines as immunological adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.167

CpG motifs in bacterial DNA trigger direct B-cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.167

CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.167

21 January 2018

Identifiers

DOI

10.1586/14760584.2.2.167

1 reference

7 August 2017

1 reference